NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Keith Flaherty, Petr Arenberger, Paolo Antonio Ascierto, Jan Willem De Groot, Sigrun Hallmeyer, Georgina V. Long, Michal Lotem, Maria Marples, Dirk Schadendorf, Alexander Starodub, Matthew Hiram Taylor, Pascal Wolter, Naoya Yamazaki, Ernesto Wasserman, James Ford, Marine Weill, Reinhard Dummer
Institutions: Massachusetts General Hospital, Charles University, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Isala, Oncology Specialists, The University of Sydney, Melanoma Institute Australia, Hadassah Medical Center, St James's University Hospital, Essen University Hospital, Indiana University Health, Goshen Health, Oregon Health & Science University, OHSU Knight Cancer Institute, Universitair Ziekenhuis Leuven, National Cancer Center Hospital, University Hospital Zurich
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2255812768